Drug Trial Radar · NCT03587805
Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND
Last checked: Nov 20, 2026Latest source record: Mar 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,672
Actual
Start
Mar 18, 2018
Primary completion
Jul 3, 2024
Study completion Jul 3, 2024
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Jul 16, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this extension trial is to evaluate the long-term safety of tralokinumab.
Conditions
- Atopic Dermatitis
Interventions
TralokinumabDrug
Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation for subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Adverse Events From Baseline Through the Last Treatment Visit (up to Week 268)Time frame: From Week 0 up to Week 268
Locations
309 sites in 11 countries. Site status is shown where the registry gives one.
LEO Pharma Investigational Site
Birmingham, Alabama
LEO Pharma Investigational Site
Birmingham, Alabama
LEO Pharma Investigational Site
Mobile, Alabama
LEO Pharma Investigational Site
Fort Smith, Arkansas
LEO Pharma Investigational Site
Bakersfield, California
LEO Pharma Investigational Site
Beverly Hills, California
LEO Pharma Investigational Site
Encinitas, California
LEO Pharma Investigational Site
Fountain Valley, California
LEO Pharma Investigational Site
Fremont, California
LEO Pharma Investigational Site
Fullerton, California
LEO Pharma Investigational Site
Los Angeles, California
LEO Pharma Investigational Site
Los Angeles, California
LEO Pharma Investigational Site
Los Angeles, California
LEO Pharma Investigational Site
Newport Beach, California
LEO Pharma Investigational Site
Northridge, California
LEO Pharma Investigational Site
Palo Alto, California
LEO Pharma Investigational Site
San Diego, California
LEO Pharma Investigational Site
San Diego, California
LEO Pharma Investigational Site
San Francisco, California
LEO Pharma Investigational Site
San Luis Obispo, California
LEO Pharma Investigational Site
Santa Ana, California
LEO Pharma Investigational Site
Santa Monica, California
LEO Pharma Investigational Site
New Haven, Connecticut
LEO Pharma Investigational Site
Clearwater, Florida
LEO Pharma Investigational Site
Doral, Florida
LEO Pharma Investigational Site
Hialeah, Florida
LEO Pharma Investigational Site
Miami, Florida
LEO Pharma Investigational Site 1
Miami, Florida
LEO Pharma Investigational Site 2
Miami, Florida
LEO Pharma Investigational Site
North Miami Beach, Florida
LEO Pharma Investigational Site
Orange Park, Florida
LEO Pharma Investigational Site
Sweetwater, Florida
LEO Pharma Investigational Site
Tampa, Florida
LEO Pharma Investigational Site
West Palm Beach, Florida
LEO Pharma Investigational Site
West Palm Beach, Florida
LEO Pharma Investigational Site
Albany, Georgia
LEO Pharma Investigational Site
Columbus, Georgia
LEO Pharma Investigational Site
Macon, Georgia
LEO Pharma Investigational Site
Newnan, Georgia
LEO Pharma Investigational Site
Savannah, Georgia
Showing 40 of 309 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.